Adial Pharmaceuticals Stock Number Of Shares Shorted

ADIL Stock  USD 0.40  0.03  7.05%   
Fundamental analysis of Adial Pharmaceuticals allows traders to better anticipate movements in Adial Pharmaceuticals' stock price by examining its financial health and performance throughout various phases of its business cycle.
  
Build AI portfolio with Adial Stock
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Adial Pharmaceuticals Company Number Of Shares Shorted Analysis

Adial Pharmaceuticals' Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.

Shares Shorted

 = 

Shorted by Public

+

by Institutions

More About Number Of Shares Shorted | All Equity Analysis

Current Adial Pharmaceuticals Number Of Shares Shorted

    
  1.23 M  
Most of Adial Pharmaceuticals' fundamental indicators, such as Number Of Shares Shorted, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Adial Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Adial Number Of Shares Shorted Driver Correlations

Understanding the fundamental principles of building solid financial models for Adial Pharmaceuticals is extremely important. It helps to project a fair market value of Adial Stock properly, considering its historical fundamentals such as Number Of Shares Shorted. Since Adial Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Adial Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Adial Pharmaceuticals' interrelated accounts and indicators.
0.940.91-0.99-0.670.570.850.680.99-0.150.48-0.84-0.220.820.950.960.54-0.22-0.22
0.940.99-0.95-0.580.440.790.390.95-0.240.2-0.76-0.220.760.990.980.3-0.22-0.22
0.910.99-0.94-0.460.430.710.330.94-0.230.16-0.71-0.170.710.970.980.31-0.17-0.17
-0.99-0.95-0.940.6-0.54-0.83-0.61-0.990.21-0.410.780.25-0.76-0.95-0.97-0.510.250.25
-0.67-0.58-0.460.6-0.39-0.92-0.55-0.570.25-0.370.640.64-0.6-0.62-0.56-0.330.640.64
0.570.440.43-0.54-0.390.550.610.570.320.25-0.72-0.170.710.50.510.5-0.17-0.17
0.850.790.71-0.83-0.920.550.620.8-0.330.38-0.72-0.540.670.810.770.45-0.54-0.54
0.680.390.33-0.61-0.550.610.620.630.130.85-0.63-0.120.60.430.480.82-0.12-0.12
0.990.950.94-0.99-0.570.570.80.63-0.140.43-0.81-0.20.80.950.980.54-0.2-0.2
-0.15-0.24-0.230.210.250.32-0.330.13-0.14-0.06-0.30.120.31-0.14-0.13-0.060.120.12
0.480.20.16-0.41-0.370.250.380.850.43-0.06-0.320.140.330.20.270.890.140.14
-0.84-0.76-0.710.780.64-0.72-0.72-0.63-0.81-0.3-0.320.31-0.97-0.83-0.82-0.390.310.31
-0.22-0.22-0.170.250.64-0.17-0.54-0.12-0.20.120.140.31-0.18-0.31-0.270.041.01.0
0.820.760.71-0.76-0.60.710.670.60.80.310.33-0.97-0.180.810.790.37-0.18-0.18
0.950.990.97-0.95-0.620.50.810.430.95-0.140.2-0.83-0.310.810.990.31-0.31-0.31
0.960.980.98-0.97-0.560.510.770.480.98-0.130.27-0.82-0.270.790.990.39-0.27-0.27
0.540.30.31-0.51-0.330.50.450.820.54-0.060.89-0.390.040.370.310.390.040.04
-0.22-0.22-0.170.250.64-0.17-0.54-0.12-0.20.120.140.311.0-0.18-0.31-0.270.041.0
-0.22-0.22-0.170.250.64-0.17-0.54-0.12-0.20.120.140.311.0-0.18-0.31-0.270.041.0
Click cells to compare fundamentals
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.
Competition

Based on the recorded statements, Adial Pharmaceuticals has 1.23 M of outstending shares currently sold short by investors. This is 61.57% lower than that of the Pharmaceuticals sector and 75.88% lower than that of the Health Care industry. The number of shares shorted for all United States stocks is 73.87% higher than that of the company.

Adial Number Of Shares Shorted Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Adial Pharmaceuticals' direct or indirect competition against its Number Of Shares Shorted to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Adial Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Adial Pharmaceuticals by comparing valuation metrics of similar companies.
Adial Pharmaceuticals is currently under evaluation in number of shares shorted category among its peers.

Adial Pharmaceuticals Current Valuation Drivers

We derive many important indicators used in calculating different scores of Adial Pharmaceuticals from analyzing Adial Pharmaceuticals' financial statements. These drivers represent accounts that assess Adial Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Adial Pharmaceuticals' important valuation drivers and their relationship over time.
202020212022202320242025 (projected)
Market Cap21.2M50.2M5.8M2.6M18.8M22.5M
Enterprise Value16.8M44.4M2.1M(177.2K)15.0M18.9M

Adial Fundamentals

About Adial Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Adial Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Adial Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Adial Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Prophet
When determining whether Adial Pharmaceuticals is a strong investment it is important to analyze Adial Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Adial Pharmaceuticals' future performance. For an informed investment choice regarding Adial Stock, refer to the following important reports:
Check out Adial Pharmaceuticals Piotroski F Score and Adial Pharmaceuticals Altman Z Score analysis.
For more information on how to buy Adial Stock please use our How to buy in Adial Stock guide.
You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adial Pharmaceuticals. If investors know Adial will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adial Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.76)
Return On Assets
(0.88)
Return On Equity
(1.71)
The market value of Adial Pharmaceuticals is measured differently than its book value, which is the value of Adial that is recorded on the company's balance sheet. Investors also form their own opinion of Adial Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Adial Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adial Pharmaceuticals' market value can be influenced by many factors that don't directly affect Adial Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Adial Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Adial Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adial Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.